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In relation to GGA type, local progression did not occur during the 
assessment period in 292 of the 341 complete-type tumors (85.6%) or 
72 of the 115 incomplete-type tumors (62.6%). The 1-, 2- and 3-year 
technique effectiveness rates as assessed by Kaplan-Meier methods 
were 77.7%, 64.8% and 60.5% for complete-type tumors and 57.8%, 
45.3% and 33.9% for incomplete-type tumors, respectively. Tumor size 
for incomplete-type group was signiﬁcantly larger than for complete 
type. (p<0.05)
Complications: The incidence of pneumothorax, pleural effusion, 
and tube placement of pneumothorax were 52.2%, 18.8%, and 20.5% 
respectively. Two patients died during the course of the study because 
of intractable pneumothorax and massive hemoptysis.
Discussion
In the present study, a signiﬁcant difference was noted between ≤2 cm 
and >2 cm tumors, but not between 2-3 cm and >3 cm tumors. Mid-
term technique effectiveness was favorable for ≤2 cm tumors. This may 
be attributable to the ablation capacity of RF systems. Since we often 
used a system with the range of ablation of a 1-3-cm sphere, complete 
ablation could be expected with tumors ≤2 cm in size. We now use 
larger LeVeen needles to overcome this problem.
Based on this report, we deﬁned complete necrosis as having a safety 
margin of ≥5 mm, and technique effectiveness rates were more favor-
able for complete-GGA-type tumors. Surrounding GGA can be as-
sessed immediately after RF ablation, and may be useable as an indica-
tor of technique effectiveness. However, local progression still occurred 
with tumors completely surrounded by GGA, so not all GGA reﬂects 
coagulative necrosis. Reasons for this include the following: degree of 
ablation cannot be assessed in areas adjacent to existing structures such 
as the pleura and/or large pulmonary vessels; GGA could be caused 
by other factors such as bleeding; and the discrepancy between range 
of GGA seen on CT and actual histopathological range of necrosis. As 
complete-type tumors were smaller than incomplete-type tumors with 
statistical signiﬁcance, GGA type can simply reﬂect tumor size.
Our study revealed that secondary technique effectiveness rates 
improved with re-RF ablation in the treatment of local progressions. 
Compared to other treatments such as surgery and radiotherapy, RF 
ablation is advantageous because therapy is easily repeated many times.
RF ablation appears to be a safe and minimally invasive option with 
negligible mortality and little morbidity in selected patients with unre-
sectable thoracic malignant tumors.
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In the last decades, thanks to the introduction of various ancillary diag-
nostic and therapeutic techniques, the role of bronchoscopy has evolved 
as an essential tool in the management of lung cancer in any step of the 
natural history of the disease.
From the early detection (autoﬂuorescence bronchoscopy) to the 
diagnosis and staging (transbronchial needle aspiration, ultrasound 
bronchoscopy), the value of bronchoscopy as a diagnostic and staging 
method is worldwide acknowledged. On the contrary, the potential 
therapeutic role of bronchoscopy in lung cancer is still underrated and 
in the ﬂow-charts of treatment modalities of lung cancer the interven-
tional pulmonology procedures are often unmentioned.
50-60% of lung cancers occurs in central airways and thus are reach-
able by bronchoscopic techniques that can be utilised with curative 
intent or for palliative care. 
Various intraluminal bronchoscopic treatment methods have been 
used with curative intent in early stage cancer of the central airways 
(carcinoma in situ or microinvasive carcinoma). Photodynamic therapy 
(PDT), endobronchial brachyterapy, laser therapy, electrocautery and 
cryotherapy have been employed in this ﬁeld. Complete response rate 
ranges from 75 to 97 % and it is higher when the tumor has a limited 
surface area less than 1 square centimeter. 
More frequently, bronchoscopic techniques are used with palliative 
intent in cases of malignant central airways obstruction in patients not 
candidate for surgery. Symptoms such as dyspnea, cough, post-obstruc-
tive pneumonia and haemoptysis are commonly present in patients with 
lung cancer and may be related to the endobronchial extension of the 
tumor. These symptoms may be life-treathening and cause of death or 
may affect the quality of life. 
There are various bronchoscopic techniques to be employed in the 
palliative treatment of endobronchial tumours. The choice depends on 
three major factors: 
1) the need to obtain an immediate effect for symptoms relief in 
patients with severe dyspnoea and imminent respiratory failure or 
life-threatening haemoptysis. Therapeutic bronchoscopy using laser, 
elctrocauthery, argon plasma coagulation and the use of stents may 
provide an immediate reopening of the airway lumen. 
2) the type of stenosis that can be related to endoluminal growing 
tumours, to extrinsic compression or to mixed pattern with intralu-
minal tissue associated with intramural spread or extrinsic compres-
sion; 
3) the local availability of facilities or experience.
In selected cases, the bronchoscopic treatment of lung cancer can 
provide faster relief of symptoms than any other treatment measure. 
Unfortunately, the endoscopic intervention is generally reserved to 
œadvanced cases”, after that oncologic treatment as chemo- or radio-
therapy have failed. On the contrary, the above mentioned procedures 
should be considered means of treatment for central airways tumours, 
that do not compete but must be integrated with other care modalities, 
even at the beginning of the therapeutical management of the patient. 
In this sense a close cooperation between the interventional pulmo-
nologist, the oncologist and the radiotherapist is an essential step to 
optimise the management of lung cancer patient.
The different techniques for disobstructing airways in patients affected 
by lung cancer will be discussed in this “Meet the Professor” Session.
